Astellas Gene Therapies

The executives we surveyed on the clinical trial landscape identified several sweeping trends that are expected to drive change over the coming year. As in so many spheres, data, digital technology an

Sentiments around the 2023 biopharma dealmaking environment may be mixed, but Mike Luther, the global head of search and evaluation business development at Astellas Pharma, Inc. , hopes the coming ye

Conditions look ripe for an uptick in M&A this year after a fairly quiet 2022, while other types of strategic deals are also expected to increase in the face of a challenging funding situation for bio

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Asia Deal Watch is supported by deal intelligence from Biomedtracker. $50m Taysha Investment Gives Astel